Chemotherapeutic potential of Cayratia trifolia L nhexane extract on A2780 cells

Area of Science:

• Pharmacology
• Molecular Biology
• Cancer Research

Background:

• Ovarian cancer remains a significant health challenge, necessitating novel therapeutic strategies.
• Cayratia trifolia (C. trifolia) is a plant with traditional medicinal uses, but its chemotherapeutic potential is underexplored.
• Targeting specific molecular pathways, such as those involving CXCR4 and HER2, is a key approach in cancer drug development.

Purpose of the Study:

• To investigate the chemotherapeutic potential of n-hexane Cayratia trifolia L. (C. trifolia) extract against A2780 ovarian cancer cell lines.
• To analyze the effect of C. trifolia extract on the mRNA and protein expression of CXCR4 and HER2 in A2780 cells.

Main Methods:

• Cell viability assays were performed to determine the inhibitory concentration (IC50) of the C. trifolia extract.
• Reverse Transcription Polymerase Chain Reaction (RT-PCR) was used to assess mRNA expression levels.
• Western blot analysis was employed to evaluate protein expression levels of CXCR4 and HER2.

Main Results:

• The n-hexane C. trifolia extract demonstrated significant inhibition of A2780 cell growth, with a low IC50 value of 46.25 ± 0.42 μg/mL.
• Treatment with C. trifolia extract led to a considerable reduction in both mRNA and protein expression of CXCR4 and HER2 in A2780 cells.

Conclusions:

• N-hexane extract of C. trifolia exhibits promising chemotherapeutic properties against A2780 ovarian cancer cells.
• The observed inhibition of cell growth and reduction in CXCR4 and HER2 expression suggest C. trifolia as a potential source for novel chemotherapeutic agents.